Quintiles scales back its 2015 projections after a mixed quarter

Quintiles' ($Q) banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance.

Quintiles CEO Tom Pike

The company's service revenue came in at just above $1 billion on the quarter, good for 2.5% growth over the same period last year. But product development, Quintiles' largest segment, slipped 2.8% to $749.5 million, a decline due in part to $36.2 million lost to unfavorable currency exchange but also to a decrease in advisory services and a jump in cancelations, the company said. Integrated healthcare services, Quintiles' consulting-driven segment, grew 19.6% to $280.5 million.

But things are looking up moving forward, the company said. Net new business grew 5.6% to $1.4 billion on the quarter, charting a book-to-bill ratio of 1.31. And that should pick things up over the next three quarters, Quintiles figures.

"As expected, our product development segment started the year slower; however, we believe this segment will accelerate in the second half of the year on the back of our more than $11 billion industry-leading backlog," CEO Tom Pike said in a statement.

Still, Quintiles is reducing its full-year guidance from between 7.5% and 9% growth over 2014 to a range of 7% to 8%, shooting for about $4.5 billion in 2015 service revenue.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.